NEW YORK, Nov. 16, 2017 /PRNewswire/ --
If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to
Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock finished Wednesday's session 2.70% lower at $2.88. A total volume of 651,804 shares was traded, which was above their three months average volume of 650,540 shares. Over the last month and the previous three months, the Company's shares have advanced 14.29% and 2.86%, respectively. Additionally, the stock has surged 174.29% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 7.65% and 28.32%, respectively. Moreover, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have a Relative Strength Index (RSI) of 53.64.
On October 31st, 2017, Catalyst Pharma announced the completion of enrollment in the LMS-003 Phase-3 trial evaluating Firdapse® (amifampridine phosphate) in patients with Lambert-Eaton Myasthenic Syndrome. The Company's second Phase-3 trial, LMS-003, is a double-blind, placebo controlled withdrawal trial, which enrolled a total of 26 subjects. Your complete research report on CPRX can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=CPRX
Shares in Burlington, Massachusetts headquartered Flexion Therapeutics Inc. jumped 3.46%, ending yesterday's session at $23.33 with a total trading volume of 916,018 shares. The stock has gained 5.85% in the previous three months and 22.66% on an YTD basis. The Company's shares are trading 4.86% above their 200-day moving average. Moreover, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 48.97.
On November 06th, 2017, Flexion Therapeutics reported financial results for the quarter ended September 30th, 2017. Net loss for Q3 2017 was $34.2 million; R&D costs increased to $12.8 million; and G&A expenses increased to $18.4 million. As of September 30th, 2017, the Company had approximately $335.1 million in cash, cash equivalents and marketable securities. A free report on FLXN is just a click away at: http://dailystocktracker.com/registration/?symbol=FLXN
On Wednesday, Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock climbed 1.08%, to close the day at $37.60. A total volume of 351,726 shares was traded. The Company's shares have advanced 48.91% on an YTD basis. The stock is trading 1.37% above its 200-day moving average. Additionally, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 41.81.
On November 08th, 2017, research firm Stifel upgraded the Company's stock rating from 'Hold' to 'Buy', with a target price of $47 per share.
On November 08th, 2017, Supernus Pharma announced that management will present an overview and update for the Company at the Jefferies 2017 London Healthcare Conference on November 16th, 2017, at 11:40 a.m. EST at Waldorf Hilton in London, UK. Management will also present at the Piper Jaffray 29th Annual Healthcare Conference on November 29th, 2017, at 8:00 a.m. EST at Lotte New York Palace Hotel in New York. Sign up for your complimentary research report on SUPN at: http://dailystocktracker.com/registration/?symbol=SUPN
Shares in Dublin, Ireland headquartered Allergan PLC ended the day 0.72% higher at $173.05. A total volume of 2.52 million shares was traded. The stock is trading below its 50-day moving average by 13.08%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 34.60.
On October 27th, 2017, Allergan announced the record and payment dates for a cash dividend of $0.70 per ordinary share for the fourth quarter of 2017. The dividend will be paid on December 15th, 2017, to shareholders of record at the close of business on November 17th, 2017. The Company also announced that its Board of Directors has approved an increase to its quarterly cash dividend for 2018 to $0.72 per ordinary share.
On November 02nd, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $250 a share to $221 a share. Register for free on DailyStockTracker.com and download the latest research report on AGN at: http://dailystocktracker.com/registration/?symbol=AGN
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/generic-drugs-stock-performance-review----catalyst-pharma-flexion-therapeutics-supernus-pharma-and-allergan-300557470.html
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All